Live attenuated influenza virus vaccines by computer-aided rational design

Nature Biotechnology

Volumn 28, Issue 7, 2010, Pages 723-726

  Mueller, Steffen ^a   Coleman, J Robert ^a,b   Papamichail, Dimitris ^b,c,d   Ward, Charles B ^b   Nimnual, Anjaruwee ^a   Futcher, Bruce ^a   Skiena, Steven ^b   Wimmer, Eckard ^a  

^a STONY BROOK UNIVERSITY   (United States)

^b Stony Brook University   (United States)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^d Department of Computer Science and Center for Computational Science   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GENES; VACCINES;

BIOMEDICAL RESEARCH; INFLUENZA VIRUS; INTRANASAL; RATIONAL DESIGN; VIRAL GENOME; WILD TYPES;

VIRUSES;

INFLUENZA VACCINE; LIVE VACCINE; CODON; VIRUS VACCINE;

ARTICLE; BIOENGINEERING; COMPUTER AIDED DESIGN; EPIDEMIC; HUMAN; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H5N1; NONHUMAN; PANDEMIC; PRIORITY JOURNAL; VIRUS GENOME; VIRUS STRAIN; WILD TYPE; ANIMAL; CELL CULTURE; CODON; DOG; GENETICS; IMMUNOLOGY; LD 50; MOLECULAR GENETICS; MOUSE; ORTHOMYXOVIRUS;

ANIMALS; CELLS, CULTURED; CODON; COMPUTER-AIDED DESIGN; DOGS; GENOME, VIRAL; LETHAL DOSE 50; MICE; MOLECULAR SEQUENCE DATA; ORTHOMYXOVIRIDAE; VIRAL VACCINES;

EID: 77954482089     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt.1636     Document Type: Article

References (25)

1. Salomon, R. & Webster, R.G. The infuenza virus enigma. Cell 136, 402-410 (2009).
2. Coleman, J.R. et al. Virus attenuation by genome-scale changes in codon-pair bias. Science 320, 1784-1787 (2008).
3. Palese, P. & Shaw, M.L. in Field's Virology, vol.2 (eds. D.M. Knipe et al.) 1647-1689, (Lippincott Williams & Wilkins, Philadelphia, 2007).
4. Steinhauer, D.A. & Skehel, J.J. Genetics of infuenza viruses. Annu. Rev. Genet. 36, 305-332 (2002).
5. Maassab, H.F. Adaptation and growth characteristics of infuenza virus at 25 degrees c. Nature 213, 612-614 (1967).
6. Rimmelzwaan, G.F., Fouchier, R.A. & Osterhaus, A.D. Infuenza virus-specifc cytotoxic T lymphocytes: a correlate of protection and a basis for vaccine development. Curr. Opin. Biotechnol. 18, 529-536 (2007).
7. Sant, A.J. et al. Immunodominance in CD4 T-cell responses: implications for immune responses to infuenza virus and for vaccine design. Expert Rev. Vaccines 6, 357-368 (2007).
8. Hikono, H. et al. T-cell memory and recall responses to respiratory virus infections. Immunol. Rev. 211, 119-132 (2006).
9. Swain, S.L. et al. CD4+ T-cell memory: generation and multi-faceted roles for CD4+ T cells in protective immunity to infuenza. Immunol. Rev. 211, 8-22 (2006).
10. Simonsen, L. et al. Impact of infuenza vaccination on seasonal mortality in the US elderly population. Arch. Intern. Med. 165, 265-272 (2005).
11. Belshe, R.B., Van Voris, L.P., Bartram, J. & Crookshanks, F.K. Live attenuated infuenza A virus vaccines in children: results of a feld trial. J. Infect. Dis. 150, 834-840 (1984).
12. Belshe, R.B. et al. The effcacy of live attenuated, cold-adapted, trivalent, intranasal infuenzavirus vaccine in children. N. Engl. J. Med. 338, 1405-1412 (1998).
13. Cello, J., Paul, A.V. & Wimmer, E. Chemical synthesis of poliovirus cDNA: generation of infectious virus in the absence of natural template. Science 297, 1016-1018 (2002).
14. Gutman, G.A. & Hatfeld, G.W. Nonrandom utilization of codon pairs in Escherichia coli. Proc. Natl. Acad. Sci. USA 86, 3699-3703 (1989).
15. Moura, G. et al. Large scale comparative codon-pair context analysis unveils general rules that fne-tune evolution of mRNA primary structure. PLoS ONE 2, e847 (2007).
16. Wimmer, E., Mueller, S., Tumpey, T.M. & Taubenberger, J.K. Synthetic viruses: a new opportunity to understand and prevent viral disease. Nat. Biotechnol. 27, 1163-1172 (2009).
17. Hoffmann, E., Neumann, G., Kawaoka, Y., Hobom, G. & Webster, R.G.A. DNA transfection system for generation of infuenza A virus from eight plasmids. Proc. Natl. Acad. Sci. USA 97, 6108-6113 (2000).
18. Schickli, J.H. et al. Plasmid-only rescue of infuenza A virus vaccine candidates. Phil. Trans. R. Soc. Lond. B 356, 1965-1973 (2001).
19. Mueller, S., Papamichail, D., Coleman, J.R., Skiena, S. & Wimmer, E. Reduction of the rate of poliovirus protein synthesis through large-scale codon deoptimization causes attenuation of viral virulence by lowering specifc infectivity. J. Virol. 80, 9687-9696 (2006).
20. Shizhen, L. Compendium of Materia Medica (Bencao Gangmu, 1593) (Foreign Language Press, 2004).
21. Hutchinson, E.C., Curran, M.D., Read, E.K., Gog, J.R. & Digard, P. Mutational analysis of cis-acting RNA signals in segment 7 of infuenza A virus. J. Virol. 82, 11869-11879 (2008).
22. Wang, Z., Tobler, S., Roayaei, J. & Eick, A. Live attenuated or inactivated infuenza vaccines and medical encounters for respiratory illnesses among US military personnel. J. Am. Med. Assoc. 301, 945-953 (2009).
23. Coffn, J.M. Attenuation by a thousand cuts. N. Engl. J. Med. 359, 2283-2285 (2008).
24. Reed, L.J. & Muench, M. A simple method for estimating ffty percent endpoints. Am. J. Hyg. 27, 493-497 (1938).
25. Quinlivan, M. et al. Attenuation of equine infuenza viruses through truncations of the NS1 protein. J. Virol. 79, 8431-8439 (2005).